Reason for discontinuation of treatment with third-line TKI
| Treatment status . | Dasatinib (n = 34), no. (%) . | Nilotinib (n = 14), no. (%) . |
|---|---|---|
| On treatment | 6 (18) | 7 (50) |
| Discontinued treatment | 28 (82) | 7 (50) |
| Side effects | 7 (21) | 0 (0) |
| Loss CHR | 6 (18) | 0 (0) |
| Died on therapy | 4 (12) | 1 (7) |
| No response | 3 (9) | 2 (14) |
| Allogeneic transplantation | 1 (3) | 2 (14) |
| Transformation | 7 (21) | 2 (14) |
| Treatment status . | Dasatinib (n = 34), no. (%) . | Nilotinib (n = 14), no. (%) . |
|---|---|---|
| On treatment | 6 (18) | 7 (50) |
| Discontinued treatment | 28 (82) | 7 (50) |
| Side effects | 7 (21) | 0 (0) |
| Loss CHR | 6 (18) | 0 (0) |
| Died on therapy | 4 (12) | 1 (7) |
| No response | 3 (9) | 2 (14) |
| Allogeneic transplantation | 1 (3) | 2 (14) |
| Transformation | 7 (21) | 2 (14) |